Search

Your search keyword '"Fléchon A"' showing total 10 results
Start Over Author "Fléchon A" Publisher american association for cancer research (aacr)
10 results on '"Fléchon A"'

1. Supplementary Table S1 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

Author

Drakaki, Alexandra, primary, Powles, Thomas, primary, Bamias, Aristotelis, primary, Martin-Liberal, Juan, primary, Shin, Sang Joon, primary, Friedlander, Terence, primary, Tosi, Diego, primary, Park, Chandler, primary, Gomez-Roca, Carlos, primary, Joly Lobbedez, Florence, primary, Castellano, Daniel, primary, Morales-Barrera, Rafael, primary, Moreno-Candilejo, Irene, primary, Fléchon, Aude, primary, Yuen, Kobe, primary, Rishipathak, Deepali, primary, DuPree, Kelly, primary, Young, Fiona, primary, Michielin, Francesca, primary, Shemesh, Colby S., primary, Steinberg, Elizabeth E., primary, Williams, Patrick, primary, and Lee, Jae Lyun, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Figure S3 from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

Author

Drakaki, Alexandra, primary, Powles, Thomas, primary, Bamias, Aristotelis, primary, Martin-Liberal, Juan, primary, Shin, Sang Joon, primary, Friedlander, Terence, primary, Tosi, Diego, primary, Park, Chandler, primary, Gomez-Roca, Carlos, primary, Joly Lobbedez, Florence, primary, Castellano, Daniel, primary, Morales-Barrera, Rafael, primary, Moreno-Candilejo, Irene, primary, Fléchon, Aude, primary, Yuen, Kobe, primary, Rishipathak, Deepali, primary, DuPree, Kelly, primary, Young, Fiona, primary, Michielin, Francesca, primary, Shemesh, Colby S., primary, Steinberg, Elizabeth E., primary, Williams, Patrick, primary, and Lee, Jae Lyun, primary

Published
2023
Full Text
View/download PDF

3. Data from Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

Author

Drakaki, Alexandra, primary, Powles, Thomas, primary, Bamias, Aristotelis, primary, Martin-Liberal, Juan, primary, Shin, Sang Joon, primary, Friedlander, Terence, primary, Tosi, Diego, primary, Park, Chandler, primary, Gomez-Roca, Carlos, primary, Joly Lobbedez, Florence, primary, Castellano, Daniel, primary, Morales-Barrera, Rafael, primary, Moreno-Candilejo, Irene, primary, Fléchon, Aude, primary, Yuen, Kobe, primary, Rishipathak, Deepali, primary, DuPree, Kelly, primary, Young, Fiona, primary, Michielin, Francesca, primary, Shemesh, Colby S., primary, Steinberg, Elizabeth E., primary, Williams, Patrick, primary, and Lee, Jae Lyun, primary

Published
2023
Full Text
View/download PDF

4. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)

Author

Drakaki, Alexandra, primary, Powles, Thomas, additional, Bamias, Aristotelis, additional, Martin-Liberal, Juan, additional, Shin, Sang Joon, additional, Friedlander, Terence, additional, Tosi, Diego, additional, Park, Chandler, additional, Gomez-Roca, Carlos, additional, Joly Lobbedez, Florence, additional, Castellano, Daniel, additional, Morales-Barrera, Rafael, additional, Moreno-Candilejo, Irene, additional, Fléchon, Aude, additional, Yuen, Kobe, additional, Rishipathak, Deepali, additional, DuPree, Kelly, additional, Young, Fiona, additional, Michielin, Francesca, additional, Shemesh, Colby S., additional, Steinberg, Elizabeth E., additional, Williams, Patrick, additional, and Lee, Jae Lyun, additional

Published
2023
Full Text
View/download PDF

5. Table S2 from Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

Author

Moeung, Sotheara, primary, Chevreau, Christine, primary, Broutin, Sophie, primary, Guitton, Jérôme, primary, Lelièvre, Bénédicte, primary, Ciccolini, Joseph, primary, Massart, Christophe, primary, Fléchon, Aude, primary, Delva, Rémy, primary, Gravis, Gwenaëlle, primary, Lotz, Jean-Pierre, primary, Bay, Jacques-Olivier, primary, Gross-Goupil, Marine, primary, Paci, Angelo, primary, Marsili, Sabrina, primary, Malard, Laurence, primary, Chatelut, Etienne, primary, and Thomas, Fabienne, primary

Published
2023
Full Text
View/download PDF

6. Figure S3 from Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

Author

Moeung, Sotheara, primary, Chevreau, Christine, primary, Broutin, Sophie, primary, Guitton, Jérôme, primary, Lelièvre, Bénédicte, primary, Ciccolini, Joseph, primary, Massart, Christophe, primary, Fléchon, Aude, primary, Delva, Rémy, primary, Gravis, Gwenaëlle, primary, Lotz, Jean-Pierre, primary, Bay, Jacques-Olivier, primary, Gross-Goupil, Marine, primary, Paci, Angelo, primary, Marsili, Sabrina, primary, Malard, Laurence, primary, Chatelut, Etienne, primary, and Thomas, Fabienne, primary

Published
2023
Full Text
View/download PDF

7. File S1 from Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

Author

Fabienne Thomas, Etienne Chatelut, Laurence Malard, Sabrina Marsili, Angelo Paci, Marine Gross-Goupil, Jacques-Olivier Bay, Jean-Pierre Lotz, Gwenaëlle Gravis, Rémy Delva, Aude Fléchon, Christophe Massart, Joseph Ciccolini, Bénédicte Lelièvre, Jérôme Guitton, Sophie Broutin, Christine Chevreau, and Sotheara Moeung

Abstract

Description of the population pharmacokinetic model used to evaluate the inter-occasion (inter-day and inter-cycle) variability.

Published
2023

8. Table S2 from Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

Author

Fabienne Thomas, Etienne Chatelut, Laurence Malard, Sabrina Marsili, Angelo Paci, Marine Gross-Goupil, Jacques-Olivier Bay, Jean-Pierre Lotz, Gwenaëlle Gravis, Rémy Delva, Aude Fléchon, Christophe Massart, Joseph Ciccolini, Bénédicte Lelièvre, Jérôme Guitton, Sophie Broutin, Christine Chevreau, and Sotheara Moeung

Abstract

Full and reduced covariate equations obtained from the model-building dataset (n = 58 patients)

Published
2023

9. Data from Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

Author

Fabienne Thomas, Etienne Chatelut, Laurence Malard, Sabrina Marsili, Angelo Paci, Marine Gross-Goupil, Jacques-Olivier Bay, Jean-Pierre Lotz, Gwenaëlle Gravis, Rémy Delva, Aude Fléchon, Christophe Massart, Joseph Ciccolini, Bénédicte Lelièvre, Jérôme Guitton, Sophie Broutin, Christine Chevreau, and Sotheara Moeung

Abstract

Purpose: We aimed to evaluate the performance of therapeutic drug monitoring (TDM) approach in controlling interpatient variability of carboplatin exposure (AUC) in patients treated with TI-CE high-dose chemotherapy for advanced germ cell tumors and to assess the possibility of using a formula-based dosing method as a possible alternative.Experimental Design: Eighty-nine patients receiving carboplatin for 3 consecutive days during 3 cycles were evaluable for pharmacokinetic study. Blood samples were taken on day 1 to determine the carboplatin clearance using a Bayesian approach (NONMEM 7.2) and to adjust the dose on day 3 to reach the target AUC of 24 mg.min/mL over 3 days. On days 2 and 3, samples were taken for retrospective assessment of the actual AUC. A population pharmacokinetic analysis was also performed on 58 patients using NONMEM to develop a covariate equation for carboplatin clearance prediction adapted for future TI-CE patients, and its performance was prospectively evaluated on the other 29 patients along with different methods of carboplatin clearance prediction.Results: The mean actual AUC was 24.4 mg.min/mL per cycle (22.4 and 26.8 for 10th and 90th percentiles, respectively). The new covariate equation [CL (mL/min) = 130.7 × (Scr/83)−0.826 × (BW/76)+0.907 × (Age/36)−0.223 with Scr in μmol/L, BW in kilograms, age in years] allows unbiased and more accurate prediction of carboplatin clearance compared with other equations.Conclusions: TDM allows controlling and reaching the target AUC. Alternatively, the new equation of carboplatin clearance prediction, better adapted to these young male patients, could be used if TDM cannot be implemented. Clin Cancer Res; 23(23); 7171–9. ©2017 AACR.

Published
2023

10. Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

Author

Moeung, Sotheara, primary, Chevreau, Christine, additional, Broutin, Sophie, additional, Guitton, Jérôme, additional, Lelièvre, Bénédicte, additional, Ciccolini, Joseph, additional, Massart, Christophe, additional, Fléchon, Aude, additional, Delva, Rémy, additional, Gravis, Gwenaëlle, additional, Lotz, Jean-Pierre, additional, Bay, Jacques-Olivier, additional, Gross-Goupil, Marine, additional, Paci, Angelo, additional, Marsili, Sabrina, additional, Malard, Laurence, additional, Chatelut, Etienne, additional, and Thomas, Fabienne, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results